{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:00:40Z","timestamp":1764403240529,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00066-023-02053-1","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T14:02:54Z","timestamp":1677765774000},"page":"761-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of PD-L1 and VISTA expression status in primary and recurrent\/refractory tissue after (chemo)radiotherapy in head and neck cancer"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7848-5437","authenticated-orcid":false,"given":"G\u00f6rkem Yaz\u0131c\u0131","family":"\u015eener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3835-2741","authenticated-orcid":false,"given":"Osman","family":"S\u00fctc\u00fco\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1385-7324","authenticated-orcid":false,"given":"Bet\u00fcl","family":"\u00d6\u011f\u00fct","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-9467","authenticated-orcid":false,"given":"Deniz Can","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0708-2291","authenticated-orcid":false,"given":"Altan","family":"Kavuncuo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9235-9592","authenticated-orcid":false,"given":"Nuriye","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-9636","authenticated-orcid":false,"given":"Ahmet","family":"\u00d6zet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-1049","authenticated-orcid":false,"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6112-8719","authenticated-orcid":false,"given":"Ye\u015fim Gaye G\u00fcler","family":"Tezel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2644-4609","authenticated-orcid":false,"given":"Nalan","family":"Aky\u00fcrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0038-3569","authenticated-orcid":false,"given":"Ozan","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"issue":"1","key":"2053_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel\u00a0RL, Miller\u00a0KD, Fuchs\u00a0HE, Jemal\u00a0A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2053_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","volume":"7","author":"EEW Cohen","year":"2019","unstructured":"Cohen\u00a0EEW, Bell\u00a0RB, Bifulco\u00a0CB, Burtness\u00a0B, Gillison\u00a0ML, Harrington\u00a0KJ et\u00a0al (2019) The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J\u00a0Immunother Cancer 7(1):184. https:\/\/doi.org\/10.1186\/s40425-019-0662-5","journal-title":"J Immunother Cancer"},{"issue":"7","key":"2053_CR3","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1002\/cncr.23654","volume":"113","author":"DM Cognetti","year":"2008","unstructured":"Cognetti\u00a0DM, Weber\u00a0RS, Lai\u00a0SY (2008) Head and neck cancer: an evolving treatment paradigm. Cancer 113(7):1911\u20131932. https:\/\/doi.org\/10.1002\/cncr.23654","journal-title":"Cancer"},{"issue":"3","key":"2053_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel\u00a0JJ, Chowell\u00a0D, Chan\u00a0TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133\u2013150. https:\/\/doi.org\/10.1038\/s41568-019-0116-x","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2053_CR5","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/s1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney\u00a0GT, Weiner\u00a0LM, Atkins\u00a0MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17(12):e542\u2013e51. https:\/\/doi.org\/10.1016\/s1470-2045(16)30406-5","journal-title":"Lancet Oncol"},{"key":"2053_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","volume":"116","author":"S Maleki Vareki","year":"2017","unstructured":"Maleki Vareki\u00a0S, Garrig\u00f3s\u00a0C, Duran\u00a0I (2017) Biomarkers of response to PD-1\/PD-L1 inhibition. Crit Rev Oncol Hematol 116:116\u2013124. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.06.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"2053_CR7","doi-asserted-by":"publisher","first-page":"104460","DOI":"10.1016\/j.oraloncology.2019.104460","volume":"99","author":"JD Cramer","year":"2019","unstructured":"Cramer\u00a0JD, Burtness\u00a0B, Ferris\u00a0RL (2019) Immunotherapy for head and neck cancer: recent advances and future directions. Oral Oncol 99:104460. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.104460","journal-title":"Oral Oncol"},{"issue":"1","key":"2053_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/imr.12525","volume":"276","author":"EC Nowak","year":"2017","unstructured":"Nowak\u00a0EC, Lines\u00a0JL, Varn\u00a0FS, Deng\u00a0J, Sarde\u00a0A, Mabaera\u00a0R et\u00a0al (2017) Immunoregulatory functions of VISTA. Immunol Rev 276(1):66\u201379. https:\/\/doi.org\/10.1111\/imr.12525","journal-title":"Immunol Rev"},{"issue":"6","key":"2053_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou\u00a0W, Chen\u00a0L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8(6):467\u2013477. https:\/\/doi.org\/10.1038\/nri2326","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2053_CR10","doi-asserted-by":"publisher","first-page":"e000683","DOI":"10.1136\/esmoopen-2020-000683","volume":"4","author":"M Tagliamento","year":"2020","unstructured":"Tagliamento\u00a0M, Bironzo\u00a0P, Novello\u00a0S (2020) New emerging targets in cancer immunotherapy: the role of VISTA. ESMO Open 4(3):e683. https:\/\/doi.org\/10.1136\/esmoopen-2020-000683","journal-title":"ESMO Open"},{"issue":"1","key":"2053_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","volume":"13","author":"X Huang","year":"2020","unstructured":"Huang\u00a0X, Zhang\u00a0X, Li\u00a0E, Zhang\u00a0G, Wang\u00a0X, Tang\u00a0T et\u00a0al (2020) VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. J\u00a0Hematol Oncol 13(1):83. https:\/\/doi.org\/10.1186\/s13045-020-00917-y","journal-title":"J Hematol Oncol"},{"key":"2053_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4519","volume-title":"A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)","author":"AX Zhu","year":"2020","unstructured":"Zhu\u00a0AX, Finn\u00a0RS, Ikeda\u00a0M, Sung\u00a0MW, Baron\u00a0AD, Kudo\u00a0M et\u00a0al (2020) A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). American Society of Clinical Oncology"},{"issue":"2","key":"2053_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00262-020-02681-x","volume":"70","author":"A Makowska","year":"2021","unstructured":"Makowska\u00a0A, Meier\u00a0S, Shen\u00a0L, Busson\u00a0P, Baloche\u00a0V, Kontny\u00a0U (2021) Anti-PD\u20111 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD\u20111 and PD-L1. Cancer Immunol Immunother 70(2):323\u2013336. https:\/\/doi.org\/10.1007\/s00262-020-02681-x","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"2053_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/2326-6066.Cir-17-0235","volume":"5","author":"L Tran","year":"2017","unstructured":"Tran\u00a0L, Allen\u00a0CT, Xiao\u00a0R, Moore\u00a0E, Davis\u00a0R, Park\u00a0SJ et al (2017) Cisplatin alters antitumor immunity and synergizes with PD-1\/PD-L1 inhibition in head and neck squamous cell carcinoma. Cancer Immunol Res 5(12):1141\u20131151. https:\/\/doi.org\/10.1158\/2326-6066.Cir-17-0235","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"2053_CR15","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Demaria","year":"2015","unstructured":"Demaria\u00a0S, Golden\u00a0EB, Formenti\u00a0SC (2015) Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1(9):1325\u20131332. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2756","journal-title":"JAMA Oncol"},{"issue":"17","key":"2053_CR16","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.Ccr-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan\u00a0MZ, Galloway\u00a0AE, Kawashima\u00a0N, Dewyngaert\u00a0JK, Babb\u00a0JS, Formenti\u00a0SC et al (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA\u20114 antibody. Clin Cancer Res 15(17):5379\u20135388. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-0265","journal-title":"Clin Cancer Res"},{"key":"2053_CR17","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fonc.2018.00612","volume":"8","author":"ZS Buchwald","year":"2018","unstructured":"Buchwald\u00a0ZS, Wynne\u00a0J, Nasti\u00a0TH, Zhu\u00a0S, Mourad\u00a0WF, Yan\u00a0W et\u00a0al (2018) Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation. Front Oncol 8:612. https:\/\/doi.org\/10.3389\/fonc.2018.00612","journal-title":"Front Oncol"},{"issue":"19","key":"2053_CR18","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris\u00a0RL, Blumenschein\u00a0G, Fayette\u00a0J, Guigay\u00a0J, Colevas\u00a0AD, Licitra\u00a0L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N\u00a0Engl J Med 375(19):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"issue":"10167","key":"2053_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/s0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen\u00a0EEW, Souli\u00e8res\u00a0D, Le Tourneau\u00a0C, Dinis\u00a0J, Licitra\u00a0L, Ahn\u00a0MJ et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a\u00a0randomised, open-label, phase 3\u00a0study. Lancet 393(10167):156\u2013167. https:\/\/doi.org\/10.1016\/s0140-6736(18)31999-8","journal-title":"Lancet"},{"key":"2053_CR20","doi-asserted-by":"publisher","first-page":"v373","DOI":"10.1093\/annonc\/mdx374.001a","volume":"28","author":"R Bahleda","year":"2017","unstructured":"Bahleda\u00a0R, Braiteh\u00a0F, Balmanoukian\u00a0A, Bra\u00f1a\u00a0I, Hodi\u00a0F, Garbo\u00a0L et al (2017) Long-term safety and clinical outcomes of atezolizumab in head and neck cancer: phase Ia trial results. Ann Oncol 28:v373","journal-title":"Ann Oncol"},{"key":"2053_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.lungcan.2016.05.007","volume":"99","author":"Y Katsuya","year":"2016","unstructured":"Katsuya\u00a0Y, Horinouchi\u00a0H, Asao\u00a0T, Kitahara\u00a0S, Goto\u00a0Y, Kanda\u00a0S et al (2016) Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer 99:4\u201310. https:\/\/doi.org\/10.1016\/j.lungcan.2016.05.007","journal-title":"Lung Cancer"},{"issue":"1","key":"2053_CR22","doi-asserted-by":"publisher","first-page":"1830524","DOI":"10.1080\/2162402x.2020.1830524","volume":"9","author":"KA Pilones","year":"2020","unstructured":"Pilones\u00a0KA, Hensler\u00a0M, Daviaud\u00a0C, Kraynak\u00a0J, Fucikova\u00a0J, Galluzzi\u00a0L et\u00a0al (2020) Converging focal radiation and immunotherapy in a\u00a0preclinical model of triple negative breast cancer: contribution of VISTA blockade. OncoImmunology 9(1):1830524. https:\/\/doi.org\/10.1080\/2162402x.2020.1830524","journal-title":"OncoImmunology"},{"issue":"1","key":"2053_CR23","doi-asserted-by":"publisher","first-page":"188386","DOI":"10.1016\/j.bbcan.2020.188386","volume":"1874","author":"T van den Ende","year":"2020","unstructured":"van den Ende\u00a0T, van den Boorn\u00a0HG, Hoonhout\u00a0NM, van Etten-Jamaludin\u00a0FS, Meijer\u00a0SL, Derks\u00a0S et al (2020) Priming the tumor immune microenvironment with chemo(radio)therapy: a systematic review across tumor types. Biochim Biophys Acta Rev Cancer 1874(1):188386. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188386","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"2053_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong\u00a0J, Le\u00a0TQ, Massarelli\u00a0E, Hendifar\u00a0AE, Tuli\u00a0R (2018) Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination. J\u00a0Immunother Cancer 6(1):46. https:\/\/doi.org\/10.1186\/s40425-018-0361-7","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2053_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41598-018-36096-7","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang\u00a0Y, Kim\u00a0TH, Fouladdel\u00a0S, Zhang\u00a0Z, Soni\u00a0P, Qin\u00a0A et al (2019) PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer. Sci Rep 9(1):566. https:\/\/doi.org\/10.1038\/s41598-018-36096-7","journal-title":"Sci Rep"},{"issue":"10","key":"2053_CR26","doi-asserted-by":"publisher","first-page":"e1356153","DOI":"10.1080\/2162402x.2017.1356153","volume":"6","author":"A Oweida","year":"2017","unstructured":"Oweida\u00a0A, Lennon\u00a0S, Calame\u00a0D, Korpela\u00a0S, Bhatia\u00a0S, Sharma\u00a0J et al (2017) Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. OncoImmunology 6(10):e1356153. https:\/\/doi.org\/10.1080\/2162402x.2017.1356153","journal-title":"OncoImmunology"},{"key":"2053_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2016.06.015","volume":"65","author":"M Hecht","year":"2016","unstructured":"Hecht\u00a0M, B\u00fcttner-Herold\u00a0M, Erlenbach-W\u00fcnsch\u00a0K, Haderlein\u00a0M, Croner\u00a0R, Gr\u00fctzmann\u00a0R et al (2016) PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a\u00a0favourable prognosis. Eur J Cancer 65:52\u201360. https:\/\/doi.org\/10.1016\/j.ejca\u00a0.2016.06.015","journal-title":"Eur J Cancer"},{"issue":"7","key":"2053_CR28","doi-asserted-by":"publisher","first-page":"e1442168","DOI":"10.1080\/2162402X.2018.1442168","volume":"7","author":"KR Patel","year":"2018","unstructured":"Patel\u00a0KR, Martinez\u00a0A, Stahl\u00a0JM, Logan\u00a0SJ, Perricone\u00a0AJ, Ferris\u00a0MJ et al (2018) Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. OncoImmunology 7(7):e1442168","journal-title":"OncoImmunology"},{"issue":"6","key":"2053_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41416-019-0541-3","volume":"121","author":"K Yoneda","year":"2019","unstructured":"Yoneda\u00a0K, Kuwata\u00a0T, Kanayama\u00a0M, Mori\u00a0M, Kawanami\u00a0T, Yatera\u00a0K et al (2019) Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J Cancer 121(6):490\u2013496. https:\/\/doi.org\/10.1038\/s41416-019-0541-3","journal-title":"Br J Cancer"},{"key":"2053_CR30","doi-asserted-by":"publisher","first-page":"608772","DOI":"10.3389\/fonc.2020.608772","volume":"10","author":"JM Qian","year":"2020","unstructured":"Qian\u00a0JM, Schoenfeld\u00a0JD (2020) Radiotherapy and immunotherapy for head and neck cancer: current evidence and challenges. Front Oncol 10:608772. https:\/\/doi.org\/10.3389\/fonc.2020.608772","journal-title":"Front Oncol"},{"issue":"2","key":"2053_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tranon.2019.11.004","volume":"13","author":"H Schoop","year":"2020","unstructured":"Schoop\u00a0H, Bregenzer\u00a0A, Halske\u00a0C, Behrens\u00a0HM, Kr\u00fcger\u00a0S, Egberts\u00a0JH et al (2020) Therapy resistance in neoadjuvantly treated gastric cancer and cancer of the gastroesophageal junction is associated with an increased expression of immune checkpoint inhibitors-comparison against a\u00a0therapy na\u00efve cohort. Transl Oncol 13(2):165\u2013176. https:\/\/doi.org\/10.1016\/j.tranon.2019.11.004","journal-title":"Transl Oncol"},{"issue":"1","key":"2053_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/jco.20.00290","volume":"39","author":"S McBride","year":"2021","unstructured":"McBride\u00a0S, Sherman\u00a0E, Tsai\u00a0CJ, Baxi\u00a0S, Aghalar\u00a0J, Eng\u00a0J et\u00a0al (2021) Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J\u00a0Clin Oncol 39(1):30\u201337. https:\/\/doi.org\/10.1200\/jco.20.00290","journal-title":"J Clin Oncol"},{"issue":"9","key":"2053_CR33","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"W Theelen","year":"2019","unstructured":"Theelen\u00a0W, Peulen\u00a0HMU, Lalezari\u00a0F, van der Noort\u00a0V, de Vries\u00a0JF, Aerts\u00a0J et al (2019) Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol 5(9):1276\u20131282. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1478","journal-title":"JAMA Oncol"},{"issue":"4","key":"2053_CR34","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.Mct-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel\u00a0SP, Kurzrock\u00a0R (2015) PD-L1 expression as a\u00a0predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14(4):847\u2013856. https:\/\/doi.org\/10.1158\/1535-7163.Mct-14-0983","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2053_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/his.13946","volume":"76","author":"MR Downes","year":"2020","unstructured":"Downes\u00a0MR, Slodkowska\u00a0E, Katabi\u00a0N, Jungbluth\u00a0AA, Xu\u00a0B (2020) Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. Histopathology 76(2):191\u2013200. https:\/\/doi.org\/10.1111\/his.13946","journal-title":"Histopathology"},{"issue":"10","key":"2053_CR36","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s41416-019-0449-y","volume":"120","author":"JH Rasmussen","year":"2019","unstructured":"Rasmussen\u00a0JH, Lelkaitis\u00a0G, H\u00e5kansson\u00a0K, Vogelius\u00a0IR, Johannesen\u00a0HH, Fischer\u00a0BM et al (2019) Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. Br J Cancer 120(10):1003\u20131006. https:\/\/doi.org\/10.1038\/s41416-019-0449-y","journal-title":"Br J Cancer"},{"issue":"10212","key":"2053_CR37","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/s0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness\u00a0B, Harrington\u00a0KJ, Greil\u00a0R, Souli\u00e8res\u00a0D, Tahara\u00a0M, de Castro\u00a0G Jr. et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a\u00a0randomised, open-label, phase 3\u00a0study. Lancet 394(10212):1915\u20131928. https:\/\/doi.org\/10.1016\/s0140-6736(19)32591-7","journal-title":"Lancet"},{"issue":"21","key":"2053_CR38","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1073\/pnas.1420370112","volume":"112","author":"J Liu","year":"2015","unstructured":"Liu\u00a0J, Yuan\u00a0Y, Chen\u00a0W, Putra\u00a0J, Suriawinata\u00a0AA, Schenk\u00a0AD et al (2015) Immune-checkpoint proteins VISTA and PD\u20111 nonredundantly regulate murine T\u2011cell responses. Proc Natl Acad Sci U S\u00a0A 112(21):6682\u20136687. https:\/\/doi.org\/10.1073\/pnas.1420370112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2053_CR39","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","volume":"30","author":"H Kakavand","year":"2017","unstructured":"Kakavand\u00a0H, Jackett\u00a0LA, Menzies\u00a0AM, Gide\u00a0TN, Carlino\u00a0MS, Saw\u00a0RPM et al (2017) Negative immune checkpoint regulation by VISTA: a\u00a0mechanism of acquired resistance to anti-PD\u20111 therapy in metastatic melanoma patients. Mod Pathol 30(12):1666\u20131676. https:\/\/doi.org\/10.1038\/modpathol.2017.89","journal-title":"Mod Pathol"},{"issue":"5","key":"2053_CR40","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00262-017-1968-0","volume":"66","author":"L Wu","year":"2017","unstructured":"Wu\u00a0L, Deng\u00a0WW, Huang\u00a0CF, Bu\u00a0LL, Yu\u00a0GT, Mao\u00a0L et\u00a0al (2017) Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunother 66(5):627\u2013636. https:\/\/doi.org\/10.1007\/s00262-017-1968-0","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2053_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3892-2","volume":"18","author":"M Zhang","year":"2018","unstructured":"Zhang\u00a0M, Pang\u00a0H\u2011J, Zhao\u00a0W, Li\u00a0Y\u2011F, Yan\u00a0L\u2011X, Dong\u00a0Z\u2011Y et al (2018) VISTA expression associated with CD8 confers a\u00a0favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer 18(1):1\u20138","journal-title":"BMC Cancer"},{"issue":"1","key":"2053_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00262-019-02434-5","volume":"69","author":"L Zong","year":"2020","unstructured":"Zong\u00a0L, Zhou\u00a0Y, Zhang\u00a0M, Chen\u00a0J, Xiang\u00a0Y (2020) VISTA expression is associated with a\u00a0favorable prognosis in patients with high-grade serous ovarian cancer. Cancer Immunol Immunother 69(1):33\u201342. https:\/\/doi.org\/10.1007\/s00262-019-02434-5","journal-title":"Cancer Immunol Immunother"},{"key":"2053_CR43","doi-asserted-by":"publisher","first-page":"583966","DOI":"10.3389\/fonc.2020.583966","volume":"10","author":"X Cao","year":"2020","unstructured":"Cao\u00a0X, Ren\u00a0X, Zhou\u00a0Y, Mao\u00a0F, Lin\u00a0Y, Wu\u00a0H et al (2020) VISTA expression on immune cells correlates with favorable prognosis in patients with triple-negative breast cancer. Front Oncol 10:583966. https:\/\/doi.org\/10.3389\/fonc.2020.583966","journal-title":"Front Oncol"},{"issue":"3","key":"2053_CR44","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/1078-0432.Ccr-15-1543","volume":"22","author":"M Vassilakopoulou","year":"2016","unstructured":"Vassilakopoulou\u00a0M, Avgeris\u00a0M, Velcheti\u00a0V, Kotoula\u00a0V, Rampias\u00a0T, Chatzopoulos\u00a0K et al (2016) Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res 22(3):704\u2013713. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1543","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2053_CR45","doi-asserted-by":"publisher","first-page":"e0142656","DOI":"10.1371\/journal.pone.0142656","volume":"10","author":"YM Lin","year":"2015","unstructured":"Lin\u00a0YM, Sung\u00a0WW, Hsieh\u00a0MJ, Tsai\u00a0SC, Lai\u00a0HW, Yang\u00a0SM et al (2015) High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS ONE 10(11):e142656. https:\/\/doi.org\/10.1371\/journal.pone.0142656","journal-title":"PLoS ONE"},{"issue":"3","key":"2053_CR46","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.3892\/ol.2018.9059","volume":"16","author":"H Liao","year":"2018","unstructured":"Liao\u00a0H, Zhu\u00a0H, Liu\u00a0S, Wang\u00a0H (2018) Expression of V\u2011domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer. Oncol Lett 16(3):3465\u20133472. https:\/\/doi.org\/10.3892\/ol.2018.9059","journal-title":"Oncol Lett"},{"key":"2053_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.oraloncology.2018.09.016","volume":"86","author":"WF Yang","year":"2018","unstructured":"Yang\u00a0WF, Wong\u00a0MCM, Thomson\u00a0PJ, Li\u00a0KY, Su\u00a0YX (2018) The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol 86:81\u201390. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.09.016","journal-title":"Oral Oncol"},{"issue":"1","key":"2053_CR48","doi-asserted-by":"publisher","first-page":"152768","DOI":"10.1016\/j.prp.2019.152768","volume":"216","author":"H Tang","year":"2020","unstructured":"Tang\u00a0H, Zhou\u00a0X, Ye\u00a0Y, Zhou\u00a0Y, Wu\u00a0C, Xu\u00a0Y (2020) The different role of PD-L1 in head and neck squamous cell carcinomas: a meta-analysis. Pathol Res Pract 216(1):152768. https:\/\/doi.org\/10.1016\/j.prp.2019.152768","journal-title":"Pathol Res Pract"},{"issue":"14","key":"2053_CR49","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/jco.2016.70.1524","volume":"35","author":"J Bauml","year":"2017","unstructured":"Bauml\u00a0J, Seiwert\u00a0TY, Pfister\u00a0DG, Worden\u00a0F, Liu\u00a0SV, Gilbert\u00a0J et al (2017) Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a\u00a0single-arm, phase II study. J\u00a0Clin Oncol 35(14):1542\u20131549. https:\/\/doi.org\/10.1200\/jco.2016.70.1524","journal-title":"J Clin Oncol"},{"issue":"19","key":"2053_CR50","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris\u00a0RL, Blumenschein\u00a0G Jr., Fayette\u00a0J, Guigay\u00a0J, Colevas\u00a0AD, Licitra\u00a0L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N\u00a0Engl J Med 375(19):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"issue":"2","key":"2053_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","volume":"119","author":"R Mehra","year":"2018","unstructured":"Mehra\u00a0R, Seiwert\u00a0TY, Gupta\u00a0S, Weiss\u00a0J, Gluck\u00a0I, Eder\u00a0JP et al (2018) Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer 119(2):153\u2013159. https:\/\/doi.org\/10.1038\/s41416-018-0131-9","journal-title":"Br J Cancer"},{"issue":"7","key":"2053_CR52","doi-asserted-by":"publisher","first-page":"E92","DOI":"10.1177\/0145561319839788","volume":"98","author":"U Aydil","year":"2019","unstructured":"Aydil\u00a0U, Akmansu\u00a0M, G\u00fcm\u00fc\u015fay \u00d6, Eravc\u0131\u00a0FC, Bakkal\u00a0FK, Yaz\u0131c\u0131 \u00d6 et\u00a0al (2019) Failure of concurrent chemoradiotherapy for organ preservation in laryngeal cancer: survival outcomes and recurrence patterns. Ear Nose Throat\u00a0J 98(7):E92\u2013e6. https:\/\/doi.org\/10.1177\/0145561319839788","journal-title":"Ear Nose Throat J"},{"issue":"5","key":"2053_CR53","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hed.21739","volume":"34","author":"IM Agra","year":"2012","unstructured":"Agra\u00a0IM, Ferlito\u00a0A, Takes\u00a0RP, Silver\u00a0CE, Olsen\u00a0KD, Stoeckli\u00a0SJ et\u00a0al (2012) Diagnosis and treatment of recurrent laryngeal cancer following initial nonsurgical therapy. Head Neck 34(5):727\u2013735. https:\/\/doi.org\/10.1002\/hed.21739","journal-title":"Head Neck"},{"issue":"2","key":"2053_CR54","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00405-010-1365-1","volume":"268","author":"E Esteller","year":"2011","unstructured":"Esteller\u00a0E, Vega\u00a0MC, L\u00f3pez\u00a0M, Quer\u00a0M, Le\u00f3n\u00a0X (2011) Salvage surgery after locoregional failure in head and neck carcinoma patients treated with chemoradiotherapy. Eur Arch Otorhinolaryngol 268(2):295\u2013301. https:\/\/doi.org\/10.1007\/s00405-010-1365-1","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"9","key":"2053_CR55","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/hed.1104","volume":"23","author":"X Le\u00f3n","year":"2001","unstructured":"Le\u00f3n\u00a0X, Quer\u00a0M, Or\u00fas\u00a0C, L\u00f3pez\u00a0M, Gras\u00a0JR, Vega\u00a0M (2001) Results of salvage surgery for local or regional recurrence after larynx preservation with induction chemotherapy and radiotherapy. Head Neck 23(9):733\u2013738. https:\/\/doi.org\/10.1002\/hed.1104","journal-title":"Head Neck"},{"issue":"12","key":"2053_CR56","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1002\/hed.24918","volume":"39","author":"AC Birkeland","year":"2017","unstructured":"Birkeland\u00a0AC, Beesley\u00a0L, Bellile\u00a0E, Rosko\u00a0AJ, Hoesli\u00a0R, Chinn\u00a0SB et\u00a0al (2017) Predictors of survival after total laryngectomy for recurrent\/persistent laryngeal squamous cell carcinoma. Head Neck 39(12):2512\u20132518. https:\/\/doi.org\/10.1002\/hed.24918","journal-title":"Head Neck"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02053-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02053-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02053-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T04:01:58Z","timestamp":1689998518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02053-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2053"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02053-1","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.Y.\u00a0\u015eener, O.\u00a0S\u00fctc\u00fco\u011flu, B.\u00a0\u00d6\u011f\u00fct, D.C.\u00a0G\u00fcven, A.\u00a0Kavuncuo\u011flu, N.\u00a0\u00d6zdemir, A.\u00a0\u00d6zet, S.\u00a0Aksoy, Y.G.G.\u00a0Tezel, N.\u00a0Aky\u00fcrek, and O.\u00a0Yaz\u0131c\u0131 declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived by the Ethics Committee of Gazi University in view of the retrospective nature of the study and all the procedures performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}